Mission & Vision
- To promote the growth and development of the most advanced medical products/therapies in Hong Kong, the Greater Bay Area and Asia
- To deliver the highest quality and the most advanced healthcare manufacturing solutions for unmet clinical needs
- One-stop solution as the development and manufacturing partner of hospitals, pharma and biotech companies for healthcare solutions in Hong Kong and the Greater Bay Area and Asia
Senior Management
Dr. Camie Chan
Chief Executive Officer
- A seasoned scientist and biotech executive
- With a B.S. (Hons) in Biotech from University of Waterloo, M.Sc. in Medical Sciences and PhD in Immunology from University of Toronto
- Postdoctoral training at Sydney Kimmel Cancer Research Center at Johns Hopkins on a prestigious NIH fellowship award. Subsequently, she became Assistant Professor at University of California, Davis, Deputy Director of the Faculty of Medicine Core Facility & Assistant Professor of Anatomy at the University of Hong Kong
- Specializes in various aspects of human transplantation and immunology with particular interests in the use of DC, NK, T cells, etc. for immunotherapy against cancer
- Numerous awards include the National Institute of Allergy and Infectious Diseases (NIAID) Developmental Research Grant from NIH
- Spearheading to launch and design the cGMP facility, and establish the existing partnerships and various projects such as CAR-T and Haplobank
Dr. Katherine Ngan
Chairperson
- President, May Cheong Group
- Honorary Doctorate of Business Administration from the Hong Kong Polytechnic University
- Honorary President, The Chinese Manufacturers’ Association of HK
- Winner of the GBA Outstanding Women Entrepreneur Award – Supreme Honorable Winner 2021
Prof. Paul Tam
Vice Chair & Scientific Co-Founder
- Specialist in Paediatric Surgery, Hong Kong Sanatorium & Hospital
- Former Provost and Deputy Vice-Chancellor, Former Acting President and Vice-Chancellor, The University of Hong Kong
- Vice President, Macau University of Science and Technology
Prof. Godfrey Chan
Chief Medical Officer & Scientific Co-Founder
- Specialist in Paediatric Haematology & Oncology, Hong Kong Sanatorium & Hospital
- Chief of Service at the Hong Kong Children’s Hospital, and Former Head of Department of Paediatrics and Adolescent Medicine at the University of Hong Kong
- Honorary Clinical Professor, Department of Paediatrics and Adolescent Medicine, The University of Hong Kong
- Clinical expert in childhood cancer and haematopoietic stem cell transplantation. His research focus is on cancer immunology and mesenchymal stem cells biology
- Multiple International Awards (ANR, SIOP, ASPR, Endeavor Executive Award-Australian Government, and Outstanding Pediatrician of APPA) for his clinical and laboratory research works on childhood neurogenic tumors and stem cells biology
Prof. Ronald Li
Founder and Board Member
- Internationally recognized expert in cardiac electrophysiology, human heart cell/ tissue engineering and pluripotent stem cells with over 200 peer-reviewed publications
- Professor-turned serial entrepreneur with experiences in public listing, M&A, privatization, etc.
- Chairman, CEO and Founder of Medera Biopharmaceutical
- Former Director of Ming-Wai Lau Centre for Reparative Medicine, Karolinska Institutet (KI), HK/Sweden
- Former Assistant, Associate and Full Professor of Johns Hopkins University, University of California, Davis and Mount Sinai Hospital of New York
- Best Study of the Year (2005) and Ground-breaking Study of the Year (2006), American Heart Association
- Top Young Faculty Award (2002, 2004), Top Young Investigator (2001), Top Postdoc Fellow (2001) of Johns Hopkins University, Young Investigator Award 1st Prize, Heart Rhythm Society (2002), Hong Kong Spirit Innovation for Good (2015), South China Morning Post, Distinguished Alumnus of University of Waterloo (2018), Distinguished Visiting Professor of University of Toronto
Prof. Marc Turner
Chair of Scientific Advisory Board
- Medical Director, Scottish National Blood Transfusion Service
- Board Chair, Global Alliance of iPSC Therapies (GAiT)
The iPSC Haplobank Initiative is a joint effort between Xellera Therapeutics and investigators of the Department of Paediatrics and Adolescent Medicine, University of Hong Kong, and Queen Mary Hospital. The project aims to create a collection of clinical-grade iPSC lines as donor materials with the most common haplotypes in the population for matching the Human Leukocyte Antigen (HLA) of individual patients in need of cell therapies.
Prof. Wanling Yang
Professor, Department of Paediatrics & Adolescent Medicine, The University of Hong Kong
Prof. Godfrey Chan
Chief Medical Officer & Scientific Co-Founder
Prof. Ronald Li
Founder & Board Member
Xellera Therapeutics is also participating in a clinical trial initiated by investigators of the Hong Kong Children’s Hospital to study the safety and feasibility of CD19 CAR T-cells in children with relapsed or refractory CD19-positive acute lymphoblastic leukaemia or lymphoma. Xellera is responsible for the manufacturing of the CAR T-cells to be used in the trial.
Renowned International Partners
Our Quality Commitment
Xellera Therapeutics designs, develops, manufactures, and distributes high quality products for research and therapeutics. We are committed to meeting our clients’ needs by providing the highest quality and safest products that are fit for their intended uses, and by complying with the licensing conditions of License for Manufacturer, the requirements of the current Good Manufacturing Practices (cGMP) and Clinical Trial Authorizations (CTA).
To ensure our Quality Policy is effectively implemented, we developed our Quality Management System (QMS) to comply with the current Good Manufacturing Practices (cGMP) standards of Pharmaceutical Inspection Co-operation Scheme (PIC/S), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA), as well as other relevant legislations and guidelines for cell and gene therapy products.